Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) is now available.
Shanghai Henlius Biotech, Inc. announced that its product, FUTUONING (Fovinaciclib Citrate Capsules), has been included in Category B of the National Drug List for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance for 2025. This inclusion, effective from January 2026, is expected to enhance the drug’s accessibility for patients with hormone receptor-positive and HER2-negative breast cancer, thereby benefiting the company’s marketing and sales efforts.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of innovative biologic drugs. The company specializes in oncology, autoimmune diseases, and other critical therapeutic areas, with a market focus on providing accessible and effective treatments.
Average Trading Volume: 1,414,381
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.71B
For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.